Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

Yes, the cancer industry is worth billions.

Yes, onko-sure is a test marketed for cancer.

But to say that onko-sure is therefore worth billions is a false enthymeme.

Every biotech CEO says "the cancer industry is worth billions" in the PR's. It's hype.

Gartner's presentation was a sales pitch and nothing more. Gartner is on the BOD of AZBio -- if he weren't, I doubt they would have let him make that sales pitch at the conference.

Patents and trademarks and Euro Mark designations for devices that are as unprofitable as Onko-Sure are basically worthless. When Radient borrowed millions and focused on Onko-Sure sales, the best they could do was $300,000 gross revenues annually. They spent $10 million just on operating costs to accomplish that.

You can't sugar-coat that kind of under-performance.